Cover Image
市場調查報告書

水痘帶狀皰疹病毒(HHV-3)感染疾病 : 開發平台分析

Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251553
出版日期 內容資訊 英文 97 Pages
訂單完成後即時交付
價格
Back to Top
水痘帶狀皰疹病毒(HHV-3)感染疾病 : 開發平台分析 Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 97 Pages
簡介

水痘帶狀皰疹病毒(HHV-3)感染疾病是皰疹病毒科所屬病毒造成的水痘與帶狀皰疹。水痘的特徵為發疹、發燒、疲勞、頭痛等,其症狀再加上帶狀疱疹特徵為水腫及胃腸不適。因素有直接暴露於感染的表面或生物、免疫系統弱化等。診斷為伴隨傳染病的典型發疹檢查,抗病毒藥物及免疫治療等藥物治療可抑制症狀。

本報告提供水痘帶狀皰疹病毒(HHV-3)感染疾病的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,以及最新的新聞和發表等訊息。

簡介

  • 調查範圍

水痘帶狀皰疹病毒(HHV-3)感染疾病 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品
  • 企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Astellas Pharma Inc.
  • Beijing Minhai Biotechnology Co., Ltd
  • Beijing Tiantan Biological Products Co., Ltd.
  • China National Pharmaceutical Group Corporation
  • ContraVir Pharmaceuticals, Inc.
  • Epiphany Biosciences, Inc.
  • Foamix Pharmaceuticals Ltd.
  • GeneOne Life Science, Inc.
  • GlaxoSmithKline Plc
  • Green Cross Corporation
  • Merck & Co., Inc.
  • NAL Pharmaceuticals Ltd.
  • ReceptoPharm, Inc.
  • Sinovac Biotech Ltd.
  • TSRL, Inc.
  • Zydus Cadila Healthcare Limited

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (麻疹 + 流行性腮腺炎(腮腺炎) + 德國麻疹 + 水痘) (四價) 疫苗
  • (麻疹 + 流行性腮腺炎(腮腺炎) + 德國麻疹 + 水痘) 疫苗
  • (麻疹 + 德國麻疹 + 水痘) 疫苗
  • acyclovir
  • amenamevir
  • 水痘 疫苗
  • FV-100
  • GLS-5100
  • GSK-1437173A
  • herpes zoster 疫苗
  • HHV-3 疫苗
  • 麻疹 + 流行性腮腺炎(腮腺炎) + 德國麻疹 + 水痘 疫苗
  • MG-1111
  • NAL-3221
  • NAL-3223
  • RKP-00156
  • RPI-78M
  • sattabacin
  • TSR-087
  • V-212
  • valomaciclovir stearate
  • 水痘帶狀皰疹疫苗

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8492IDB

Summary

Global Markets Direct's, 'Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2016', provides an overview of the Varicella Zoster (HHV-3) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Varicella Zoster (HHV-3) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Varicella Zoster (HHV-3) Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Varicella Zoster (HHV-3) Infections
  • The report reviews pipeline therapeutics for Varicella Zoster (HHV-3) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Varicella Zoster (HHV-3) Infections therapeutics and enlists all their major and minor projects
  • The report assesses Varicella Zoster (HHV-3) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Varicella Zoster (HHV-3) Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Varicella Zoster (HHV-3) Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Varicella Zoster (HHV-3) Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Varicella Zoster (HHV-3) Infections Overview
  • Therapeutics Development
    • Pipeline Products for Varicella Zoster (HHV-3) Infections - Overview
    • Pipeline Products for Varicella Zoster (HHV-3) Infections - Comparative Analysis
  • Varicella Zoster (HHV-3) Infections - Therapeutics under Development by Companies
  • Varicella Zoster (HHV-3) Infections - Therapeutics under Investigation by Universities/Institutes
  • Varicella Zoster (HHV-3) Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Varicella Zoster (HHV-3) Infections - Products under Development by Companies
  • Varicella Zoster (HHV-3) Infections - Products under Investigation by Universities/Institutes
  • Varicella Zoster (HHV-3) Infections - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc.
    • Beijing Minhai Biotechnology Co., Ltd
    • Beijing Tiantan Biological Products Co., Ltd.
    • ContraVir Pharmaceuticals, Inc.
    • Epiphany Biosciences, Inc.
    • Foamix Pharmaceuticals Ltd.
    • GeneOne Life Science, Inc.
    • GlaxoSmithKline Plc
    • Green Cross Corporation
    • Merck & Co., Inc.
    • N & N Pharmaceuticals Inc.
    • NAL Pharmaceuticals Ltd.
    • NanoViricides, Inc.
    • ReceptoPharm, Inc.
    • Sinovac Biotech Ltd.
    • SK Chemicals Co., Ltd.
    • TSRL, Inc.
    • XBiotech Inc
    • Zydus Cadila Healthcare Limited
  • Varicella Zoster (HHV-3) Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (measles + mumps + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • acyclovir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amenamevir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chickenpox vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FV-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GLS-5100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-1437173A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • herpes zoster vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HHV-3 vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • measles + mumps + rubella + varicella vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MG-1111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Shingles - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAL-3221 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAL-3223 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NBP-608 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RKP-00156 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPI-78M - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sattabacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Shingles - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TSR-087 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • V-212 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • valomaciclovir stearate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • varicella zoster vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Varicella Zoster (HHV-3) Infections - Dormant Projects
  • Varicella Zoster (HHV-3) Infections - Discontinued Products
  • Varicella Zoster (HHV-3) Infections - Product Development Milestones
    • Featured News & Press Releases
      • Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM
      • Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles
      • Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug
      • Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study
      • Oct 27, 2015: GSK's candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over
      • Oct 26, 2015: Sinovac Receives Clinical Trial Approval for Varicella Vaccine Candidate
      • Sep 08, 2015: Clinical trial for Cardiff's shingles treatment
      • Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain
      • Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial
      • Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied
      • Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN
      • Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint
      • Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant
      • Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles
      • Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Varicella Zoster (HHV-3) Infections, H2 2016
  • Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by Astellas Pharma Inc., H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016
  • aricella Zoster (HHV-3) Infections - Pipeline by Epiphany Biosciences, Inc., H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by GeneOne Life Science, Inc., H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by Green Cross Corporation, H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by Merck & Co., Inc., H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by N & N Pharmaceuticals Inc., H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by NAL Pharmaceuticals Ltd., H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by NanoViricides, Inc., H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by ReceptoPharm, Inc., H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by Sinovac Biotech Ltd., H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by SK Chemicals Co., Ltd., H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by TSRL, Inc., H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by XBiotech Inc, H2 2016
  • Varicella Zoster (HHV-3) Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Varicella Zoster (HHV-3) Infections - Dormant Projects, H2 2016
  • Varicella Zoster (HHV-3) Infections - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Varicella Zoster (HHV-3) Infections, H2 2016
  • Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top